Global multiple sclerosis drugs market will reach $29.97 billion by 2027, growing by 4.3% annually over 2020-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs.
Highlighted with 87 tables and 87 figures, this 163-page report “Global Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Region: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire global multiple sclerosis drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global multiple sclerosis drugs market in every aspect of the classification from perspectives of Drug Type, Drug Class, Drug Category, Route of Administration, MS Type, Distribution Channel, and Region.
Based on Drug Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Immunomodulators
o Copaxone
o Avonex/Plegridy
o Gilneya
o Tysabri
o Betaseron/Extavia
o Tecifidera
o Rebif
o Ampyra
o Other Immunomodulators
• Immunosuppressants
o Aubagio
o Lemtrada
o Ocrelizumab
o Zinbryta
o Other Immunosuppressants
Based on Drug Class, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Monoclonal Antibodies
• Interferon Beta
• Sphingosine 1 Phosphate Receptor Modulators
• Mixed Polymers
• NF-κB Inhibitor
• Pyrimidine Synthesis Inhibitor
• Corticosteroids
• Adrenocorticotropic Hormone
• Other Drug Classes
Based on Drug Category, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Large-molecule Drugs
• Small-molecule Drugs
Based on Route of Administration, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Oral Administration
• Parenteral Administration
Based on MS Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Relapsing-remitting MS (RRMS)
• Primary-progressive MS (PPMS)
• Secondary-progressive MS (SPMS)
• Progressive-relapsing MS (PRMS)
Based on Distribution Channel, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Geographically, the following regions together with the listed national/local markets are fully investigated:
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of all regional markets by country and split of key national markets by Drug Type, Route of Administration, and Distribution Channel over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbvie, Inc.
Acorda Therapeutics Inc.
Bayer AG
Biogen Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Merck KgaA
Mylan NV
Novartis AG
Pfizer Inc.
Sanofi SA
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 21
2.1 Market Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 24
2.2 Major Growth Drivers 26
2.3 Market Restraints and Challenges 31
2.4 Emerging Opportunities and Market Trends 35
2.5 Porter’s Fiver Forces Analysis 39
3 Segmentation of Global Market by Drug Type 43
3.1 Market Overview by Drug Type 43
3.2 Immunomodulators 45
3.3 Immunosuppressants 47
4 Segmentation of Global Market by Drug Class 49
4.1 Market Overview by Drug Class 49
4.2 Monoclonal Antibodies 51
4.3 Interferon Beta 52
4.4 Sphingosine 1 Phosphate Receptor Modulators 53
4.5 Mixed Polymers 54
4.6 NF-κB Inhibitor 55
4.7 Pyrimidine Synthesis Inhibitor 56
4.8 Corticosteroids 57
4.9 Adrenocorticotropic Hormone 58
4.10 Other Drug Classes 59
5 Segmentation of Global Market by Drug Category 60
5.1 Market Overview by Drug Category 60
5.2 Large-molecule Drugs 62
5.3 Small-molecule Drugs 63
6 Segmentation of Global Market by Route of Administration 64
6.1 Market Overview by Route of Administration 64
6.2 Oral Administration 66
6.3 Parenteral Administration 67
7 Segmentation of Global Market by MS Type 68
7.1 Market Overview by MS Type 68
7.2 Relapsing-remitting MS (RRMS) 70
7.3 Primary-progressive MS (PPMS) 71
7.4 Secondary-progressive MS (SPMS) 72
7.5 Progressive-relapsing MS (PRMS) 73
8 Segmentation of Global Market by Distribution Channel 74
8.1 Market Overview by Distribution Channel 74
8.2 Hospital Pharmacies 76
8.3 Retail Pharmacies 77
8.4 Online Pharmacies 78
9 Segmentation of Global Market by Region 79
9.1 Geographic Market Overview 2020-2027 79
9.2 North America Market 2020-2027 by Country 83
9.2.1 Overview of North America Market 83
9.2.2 U.S. 86
9.2.3 Canada 89
9.2.4 Mexico 91
9.3 European Market 2020-2027 by Country 93
9.3.1 Overview of European Market 93
9.3.2 UK 96
9.3.3 France 98
9.3.4 Germany 100
9.3.5 Spain 102
9.3.6 Italy 104
9.3.7 Russia 106
9.3.8 Rest of European Market 108
9.4 Asia-Pacific Market 2020-2027 by Country 110
9.4.1 Overview of Asia-Pacific Market 110
9.4.2 China 113
9.4.3 Japan 115
9.4.4 India 118
9.4.5 Australia 120
9.4.6 South Korea 122
9.4.7 Rest of APAC Region 124
9.5 South America Market 2020-2027 by Country 126
9.5.1 Argentina 129
9.5.2 Brazil 131
9.5.3 Chile 133
9.5.4 Rest of South America Market 135
9.6 MEA Market 2020-2027 by Country 136
9.6.1 UAE 139
9.6.2 Saudi Arabia 141
9.6.3 South Africa 143
9.6.4 Other National Markets 145
10 Competitive Landscape 146
10.1 Overview of Key Vendors 146
10.2 New Product Launch, Partnership, Investment, and M&A 149
10.3 Company Profiles 150
Abbvie, Inc. 150
Acorda Therapeutics Inc. 152
Bayer AG 153
Biogen Inc. 154
Bristol-Myers Squibb Company 155
F. Hoffmann-La Roche Ltd. 156
Merck KgaA 157
Mylan NV 158
Novartis AG 159
Pfizer Inc. 160
Sanofi SA 161
Teva Pharmaceutical Industries Ltd. 162
RELATED REPORTS 163
Table 1. Snapshot of Global Multiple Sclerosis Drugs Market in Balanced Perspective, 2020-2027 19
Table 2. Growth Rate of World GDP, 2020-2022 23
Table 3. World Health Spending by Region, $ bn, 2013-2020 30
Table 4. Price Comparison of Commonly Used Multiple Sclerosis Medications 33
Table 5. Main Adverse Effects of Multiple Sclerosis Drugs 34
Table 6. Main Product Trends and Market Opportunities in Global Multiple Sclerosis Drugs Market 35
Table 7. Global Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 43
Table 8. Global Multiple Sclerosis Drugs Market: Immunomodulators by Drug, 2017-2027, $ mn 46
Table 9. Global Multiple Sclerosis Drugs Market: Immunosuppressants by Drug, 2017-2027, $ mn 48
Table 10. Global Multiple Sclerosis Drugs Market by Drug Class, 2017-2027, $ mn 49
Table 11. Global Multiple Sclerosis Drugs Market by Drug Category, 2017-2027, $ mn 60
Table 12. Global Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 64
Table 13. Global Multiple Sclerosis Drugs Market by MS Type, 2017-2027, $ mn 68
Table 14. Global Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 74
Table 15. Global Multiple Sclerosis Drugs Market by Region, 2017-2027, $ mn 80
Table 16. Leading National Multiple Sclerosis Drugs Market, 2020 and 2027, $ mn 82
Table 17. North America Multiple Sclerosis Drugs Market by Country, 2017-2027, $ mn 85
Table 18. U.S. Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 88
Table 19. U.S. Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 88
Table 20. U.S. Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 88
Table 21. Canada Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 90
Table 22. Canada Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 90
Table 23. Canada Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 90
Table 24. Mexico Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 92
Table 25. Mexico Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 92
Table 26. Mexico Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 92
Table 27. Europe Multiple Sclerosis Drugs Market by Country, 2017-2027, $ mn 95
Table 28. UK Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 97
Table 29. UK Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 97
Table 30. UK Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 97
Table 31. France Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 99
Table 32. France Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 99
Table 33. France Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 99
Table 34. Germany Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 101
Table 35. Germany Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 101
Table 36. Germany Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 101
Table 37. Spain Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 103
Table 38. Spain Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 103
Table 39. Spain Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 103
Table 40. Italy Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 105
Table 41. Italy Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 105
Table 42. Italy Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 105
Table 43. Russia Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 107
Table 44. Russia Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 107
Table 45. Russia Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 107
Table 46. Multiple Sclerosis Drugs Market in Rest of Europe by Country, 2017-2027, $ mn 109
Table 47. APAC Multiple Sclerosis Drugs Market by Country, 2017-2027, $ mn 112
Table 48. China Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 114
Table 49. China Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 114
Table 50. China Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 114
Table 51. Japan Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 117
Table 52. Japan Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 117
Table 53. Japan Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 117
Table 54. India Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 119
Table 55. India Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 119
Table 56. India Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 119
Table 57. Australia Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 121
Table 58. Australia Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 121
Table 59. Australia Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 121
Table 60. South Korea Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 123
Table 61. South Korea Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 123
Table 62. South Korea Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 123
Table 63. Multiple Sclerosis Drugs Market in Rest of APAC by Country/Region, 2017-2027, $ mn 125
Table 64. South America Multiple Sclerosis Drugs Market by Country, 2017-2027, $ mn 128
Table 65. Argentina Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 130
Table 66. Argentina Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 130
Table 67. Argentina Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 130
Table 68. Brazil Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 132
Table 69. Brazil Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 132
Table 70. Brazil Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 132
Table 71. Chile Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 134
Table 72. Chile Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 134
Table 73. Chile Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 134
Table 74. MEA Multiple Sclerosis Drugs Market by Country, 2017-2027, $ mn 138
Table 75. UAE Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 140
Table 76. UAE Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 140
Table 77. UAE Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 140
Table 78. Saudi Arabia Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 142
Table 79. Saudi Arabia Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 142
Table 80. Saudi Arabia Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 142
Table 81. South Africa Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 144
Table 82. South Africa Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 144
Table 83. South Africa Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 144
Table 84. Abbvie, Inc.: Company Snapshot 150
Table 85. Abbvie, Inc.: Business Segmentation 150
Table 86. Abbvie, Inc.: Product Portfolio 151
Table 87. Abbvie, Inc.: Revenue, 2017-2019, $ mn 151
